Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double-blind, placebo-controlled phase 2 trial.

Brian E LacyJennifer KingDenise ShortinoChris SchaumburgCornelia Haag-MolkentellerWilliam D Chey

Published in: Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society (2022)

In women with IBS-D, vibegron was not associated with significant improvement in the percentage of API weekly responders. Vibegron was generally safe and well tolerated and, in particular, did not worsen IBS symptoms vs. placebo.

Keyphrases

irritable bowel syndrome
placebo controlled
double blind
phase iii
clinical trial
phase ii
study protocol
phase ii study
polycystic ovary syndrome
pregnancy outcomes
squamous cell carcinoma
insulin resistance
physical activity
cervical cancer screening
sleep quality